Anbio Biotechnology (NNNN) Cash & Equivalents (2023 - 2025)

Anbio Biotechnology (NNNN) has 3 years of Cash & Equivalents data on file, last reported at $7.8 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 33.96% year-over-year to $7.8 million in Q4 2025; TTM through Dec 2025 was $7.8 million, a 33.96% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 33.96% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $7.8 million, down from $5348.5 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for NNNN reached as high as $5348.5 billion in Q2 2025 and fell as low as $7.8 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $1337.1 billion across 3 years, with a median of $10.7 million in 2023.
• Across the five-year window, Cash & Equivalents increased 21.4% in 2024 and plunged 33.96% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $9.7 million in 2023, then climbed by 21.4% to $11.8 million in 2024, then plunged by 33.96% to $7.8 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.8 million in Q4 2025, $5348.5 billion in Q2 2025, and $11.8 million in Q4 2024.